Rexahn Pharmaceuticals Inc. (RNN)

Trade RNN now with
8/6/2018 8:12:39 AM Rexahn Pharma Q2 Net Loss $3.8 Mln Or $0.12/Shr Vs Income Of $0.9 Mln Or $0.04/Shr Last Year
6/14/2018 10:01:14 AM Rexahn Announces Adjournment Of AGM Until June 27, 2018
6/4/2018 8:10:50 AM Rexahn Pharma Says Preliminary Data From Phase 2a Clinical Trial Of RX-5902; Updated Data From Phase 2a Trial Of RX-3117
5/7/2018 8:10:56 AM Rexahn Q1 Loss Per Share $0.07 Vs Loss $0.91 Last Year
3/12/2018 8:09:13 AM Rexahn Pharma FY Net Loss $25.3 Mln Or $0.92/Shr Vs Loss Of $9.3 Mln Or $0.43/Shr Last Year
2/12/2018 8:15:30 AM Rexahn Reports Data From Ongoing Phase 2a Clinical Trial Of RX-3117 In Advanced Bladder Cancer At ASCO GU
2/8/2018 8:12:57 AM Rexahn Pharma Unveils Collaboration With Zhejiang Haichang For Development Of RX-0201 For Hepatocellular Carcinoma
1/29/2018 8:10:35 AM Rexahn Receives Notice Of Allowance For New U.S. Patent Covering The Use Of RX-5902 (Supinoxin)
1/22/2018 7:32:29 AM Rexahn Pharma Announces Poster Presentation Of RX-3117 Data In Metastatic Pancreatic Patients
1/4/2018 9:04:36 AM Rexahn Pharma Names Douglas Swirsky President And CFO
12/28/2017 4:26:12 AM Watch These 6 Biotech Stocks
11/8/2017 9:09:51 AM Rexahn Doses First Patient In Phase IIa Trial Of RX-3117 In Combination With Abraxane
10/10/2017 9:06:09 AM Rexahn Receives Positive Opinion From European Medicines Agency For Orphan Drug Designation For RX-3117
9/1/2017 9:03:18 AM Rexahn Pharmaceuticals Reports Retirement Of Its Founder, Chang Ahn, From Board
8/30/2017 9:05:18 AM Rexahn Pharma Receives New U.S. Patent For Supinoxin; Patent Protection Extended Until 2034
8/7/2017 9:07:11 AM Rexahn Q2 Net Income $0.9 Mln Or $0.04 Per Basic Share